-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.Börse NYSE New York Stock ExchangeISIN US5324571083-
Eli Lilly and CoBörse NYSE New York Stock ExchangeISIN US5324571083Symbol LLY-WD
-
Eli LillyBörse Börse StuttgartISIN XS1240751229Symbol LLY
-
Eli Lilly and CompanyBörse Xetra FrankfurtISIN US532457BV93Symbol LLY
-
ELI LILLY & COBörse Börse BerlinISIN XS1240751062Symbol LLY
-
ELI LILLY & COBörse Börse HamburgISIN XS2075937370Symbol LLY
-
ELI LILLY & COBörse Gettex System der Börse MünchenISIN US532457BS64Symbol LLY
-
ELI LILLY & COBörse Quotrix System der Börse DüsseldorfISIN XS1240750767Symbol LLY
-
ELI LILLY & COBörse Tradegate System der Deutsche Börse AG (60%)ISIN US532457BR81Symbol LLY
-
ELI LILLY & COBörse Börse DüsseldorfISIN US532457AZ17Symbol LLY
-
ELI LILLY & COBörse Börse MünchenSymbol LLY
-
ELI LILLY & COBörse Börse FrankfurtSymbol LLY
-
ISIN US5324571083 WKN: 858560Symbol LLY
-
Eli Lilly and CompanyBörse Bolsa Mexicana de Valore Mexiko-StadtISIN US532457BY33
-
Eli Lilly and CompanyBörse London Stock ExchangeISIN US532457BZ08
-
Eli Lilly and CompanyBörse BVMFISIN US532457BQ09
-
Eli Lilly and CompanyBörse Bolsa de Comercio de Buenos AiresISIN US532457BH00
-
Die einen sagen so, die anderen so... Es gibt 3 Datenquellen:
178.584.305.664 oder 193.976.000.000 oder 115.268.082.559
Die einen sagen so, die anderen so... Es gibt 3 Datenquellen:
35.065 oder 33.625 oder 39.000 Mitarbeiter
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
30.54 oder 14.7
Zahlte zuletzt am 13.05.2021 eine Dividende von 0,85 USD . Seit damals wurde keine Dividende mehr ausgeschüttet Übersicht
Die Dividendenrendite
entsprach 85,67 % p. a.
beim aktuellen Kurs von 204,3 EUR +0,64%
Die letzten Quartalsergebnisse Erwarteter Gewinn je Aktie beim aktuellen Wert von 204,3 EUR +0,64%
Aktionärsstruktur der Eli Lilly and Company
Portrait der Eli Lilly Aktie
Das Unternehmen Eli Lilly and Company aus USA beschäftigt 35.897 Mitarbeiter und ist in den Bereichen Chemie & Pharma, Einzelhandel (Medikamente), Einzelhandel, Pharma tätig.
Das Unternehmen Eli Lilly and Company ist in mehr als 72 ETFs enthalten und somit ein eher allgemein bekannter Wert. Der Spitzenreiter VanEck Vectors Pharmaceutical ETF gewichtet Eli Lilly mit 5,66% im ETF.
Entdecke die 6 ETFs in denen Eli Lilly and Company am höchsten gewichtet ist Insgesamt in 72 ETFs enthalten
Dir gefallen die Informationen zu Eli Lilly?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Dir gefallen die Informationen zu Eli Lilly?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Dir gefallen die Informationen zu Eli Lilly?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Dir gefallen die Informationen zu Eli Lilly?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
196 News & Informationen zur Eli Lilly Aktie
10 Biotech Penny Stocks to Buy According to Reddit
In this article, we discuss the 10 biotech penny stocks to buy according to Reddit.
Eli Lilly (LLY) Reports Mix Q2 Financial Results
Eli Lilly and Co. (NYSE:LLY) was founded by a pharmacist named Colonel Eli Lilly way back in 1876.
Global Cancer Therapies Market to Reach $204.2 Billion by 2024
/PRNewswire/ — A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled…
Global Osteoporosis Therapeutics Market to Reach $13.1 Billion by 2024
/PRNewswire/ — A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled…
Faze Medicines Appoints New Senior Vice President, Head Of People & Culture
BOSTON, Aug. 5, 2021 /PRNewswire/ — Faze Medicines, a biotechnology company pioneering therapeutics based on the groundbreaking new science of biomolecular
Rigel Pharmaceuticals : Reports Second Quarter 2021 Financial Results and Provides Business Update (Form 8-K)
Rigel Reports Second Quarter 2021 Financial Results and Provides Business Update
–
Net product sales of $17.1 million and total… | August 3, 2021
S&P 500 Rides Energy, Health Care to Close at Record By Investing.com
S&P 500 Rides Energy, Health Care to Close at Record
Eli Lilly and Company (LLY) CEO David Ricks on Q2 2021 Results – Earnings Call Transcript
Eli Lilly and Company (NYSE:LLY) Q2 2021 Results Conference Call August 3, 2021 9:00 AM ET Company Participants Kevin Hern – VP, IR David Ricks – Chairman, CEO & President Anat…
S&P 500 Climbs as Energy, Industrials Shine By Investing.com
S&P 500 Climbs as Energy, Industrials Shine
Eli Lilly and Company 2021 Q2 – Results – Earnings Call Presentation (NYSE:LLY)
The following slide deck was published by Eli Lilly and Company in conjunction with their 2021 Q2 earnings call.
5 things to know before the stock market opens Tuesday
Dow futures gained more than 150 points Tuesday, a day after the 30-stock average gave up early gains and lost nearly 100 points.
Drugmaker Eli Lilly profit slips on weak demand for COVID-19 therapies By Reuters
Drugmaker Eli Lilly profit slips on weak demand for COVID-19 therapies
5 Stocks To Watch For August 3, 2021
Some of the stocks that may grab investor focus today are: Wall Street expects Alibaba Group Holding Ltd – ADR (NYSE: BABA) to report quarterly earnings at …
First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development
Breakthrough results in the treatment of a type of heart failure, which is extremely difficult to manage Strong progress in mental health pipeline Good…
US stocks edge down on virus woes, slowing economy
The S&P 500 Index closed slightly lower on Monday after erasing early gains as worries about the Delta variant of the coronavirus and a slowing US economy overshadowed optimism around more fiscal stimulus and a strong second-quarter earnings season.
CytRx : Announces Director Election Results from 2021 Annual Meeting of Stockholders (Form 8-K)
CytRx Announces Director Election Results from 2021 Annual Meeting of Stockholders
New Director Dr. Jennifer K. Simpson Added to CytRx Board of Directors
July… | July 30, 2021
15 Most Valuable Biotech Companies in the World
In this article we will take a look at the 15 most valuable biotech companies in the world. You can skip our detailed analysis of the biotechnology industry…
Eli Lilly and : Lilly releases donanemab data that demonstrated relationship between reduction of amyloid plaque and slowing of cognitive decline
INDIANAPOLIS, July 29, 2021 /PRNewswire/ — Today at the Alzheimer's Association International Conference© , Eli Lilly and Company presented two new exploratory analyses of data from the… | July 29, 2021
Lilly releases donanemab data that demonstrated relationship between reduction of amyloid plaque and slowing of cognitive decline
/PRNewswire/ — Today at the Alzheimer's Association International Conference© (AAIC© 2021), Eli Lilly and Company (NYSE: LLY) presented two new exploratory…
Crohn's Disease Market Set to Observe Remunerative Growth at a CAGR of 7.6% During the Study Period 2018-30
/PRNewswire/ — DelveInsight's Crohn's Disease (CD) Market report offers comprehensive coverage of the current treatment practices, pipeline drugs, Crohn's…
FDA broadens existing emergency use of Lilly and Incyte's baricitinib in patients hospitalized with COVID-19 requiring oxygen
/PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today the U.S. Food and Drug Administration (FDA) has broadened the…
FDA broadens existing emergency use of Lilly and Incyte's baricitinib in patients hospitalized with COVID-19 requiring oxygen
INDIANAPOLIS, July 29, 2021 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today the U.S. Food and Drug Admi…
Rubius Therapeutics Appoints Dannielle Appelhans As Chief Operating Officer
CAMBRIDGE Mass., July 29, 2021 (GLOBE NEWSWIRE) — Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically
Dicerna Announces FDA Clearance Of Investigational New Drug (IND) Application For DCR-AUD For The Treatment Of Alcohol Use Disorder
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (“Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi)
Domino’s, Eli Lilly, McDonald’s, Merck and More Tuesday Afternoon Analyst Upgrades and Downgrades – 24
24/7 Wall St. looks at some big analyst upgrades and downgrades that we have seen so far on Tuesday, including Domino’s, Eli Lilly, Harley-Davidson, McDonald’s and Merck.
Global Polycythemia Vera Therapeutics Market to Surpass US$ 1,516.5 Million by 2028, Says Coherent Market Insights (CMI)
SEATTLE, July 27, 2021 (GLOBE NEWSWIRE) — According to Coherent Market Insights, the global polycythemia vera therapeutics market is estimated to be…
Rigel Announces Conference Call And Webcast To Report Second Quarter 2021 Financial Results And Business Update
SOUTH SAN FRANCISCO, Calif., July 27, 2021 /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its second quarter
3 Biotech Stocks That Could Rocket Higher
Over the past year, these small-cap drugmakers have done well by their shareholders, and more big catalysts could be coming.
Worldwide Rapid Acting Insulin Industry to 2027 – Players Include Merck & Co, Sanofi and Novo Nordisk Among Others
/PRNewswire/ — The “Global Rapid Acting Insulin Market By Product Type, By Indication, By Distribution Channel, By Regional Outlook, Industry Analysis Report…
Worldwide Rapid Acting Insulin Industry To 2027 – Players Include Merck & Co, Sanofi And Novo Nordisk Among Others
DUBLIN, July 22, 2021 /PRNewswire/ — The “Global Rapid Acting Insulin Market By Product Type, By Indication, By Distribution Channel, By Regional Outlook,
Hedge Funds Never Been Less Bullish On Novartis AG (NVS)
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million holdings threshold to file a report that shows their…
Lilly Confirms Date and Conference Call for Second-Quarter 2021 Financial Results Announcement
/PRNewswire/ — Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2021 financial results on Tuesday, August 3, 2021. Lilly will also conduct a…
Glenmark Life Sciences IPO opens on July 27: 10 things to know before the issue
Glenmark Life Sciences IPO: The company plans to raise Rs 1,497.85 crore at the lower end and Rs 1,513.6 crore at the higher end of the price band.
Global Telemedicine Market Market Report 2021-21026 with Analysis of CEVA, Inc, Eli Lilly and Co, Bayer AG, Merck & Co, Teladoc Health, Inc.
/PRNewswire/ — The “Telemedicine Market, Global Forecast Impact of COVID-19, Industry Trends, Growth, Opportunity Company Overview, Financial Insight” report…
Global Telemedicine Market Market Report 2021-21026 With Analysis Of CEVA, Inc, Eli Lilly And Co, Bayer AG, Merck & Co, Teladoc Health, Inc.
DUBLIN, July 21, 2021 /PRNewswire/ — The “Telemedicine Market, Global Forecast Impact of COVID-19, Industry Trends, Growth, Opportunity Company Overview,
Dicerna Announces Interim Results From Phase 1 Trial Of Belcesiran For Treatment Of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi)